# MInimal Residual Disease Adapted Strategy

> **NCT04934475** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Intergroupe Francophone du Myelome** · enrollment: 791 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab
- **PROCEDURE:** ASCT

## Key facts

- **NCT ID:** NCT04934475
- **Lead sponsor:** Intergroupe Francophone du Myelome
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-08
- **Primary completion:** 2024-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 791 (ACTUAL)
- **Last updated:** 2024-11-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04934475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04934475, "MInimal Residual Disease Adapted Strategy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04934475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*